Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Rhea-AI Summary
Design Therapeutics (Nasdaq:DSGN), a clinical-stage biotech, will host an investor webcast on May 18, 2026, to review data from the ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich’s ataxia.
The conference call and webcast begin at 8:00 a.m. ET and will be archived for at least 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DSGN
On the day this news was published, DSGN declined 25.54%, reflecting a significant negative market reaction. Argus tracked a peak move of +37.6% during that session. Argus tracked a trough of -34.2% from its starting point during tracking. Our momentum scanner triggered 79 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $308M from the company's valuation, bringing the market cap to $897.51M at that time. Trading volume was exceptionally heavy at 7.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
